NEW YORK, Dec. 12 — MDS Pharma Services and Iconix Pharmaceuticals announced Wednesday an agreement to develop a new system to evaluate drug efficacy and toxicity. The system, called DrugMatrix, will combine chemical, genomic, and pharmacological information to allow for rapid profiling of drug candidates. Incyte, which entered an agreement with and made an equity investment in Iconix in May 2001, will commercialize the new platform.
The two firms will collaborate on developing the system. Montreal-based MDS Pharma Services will make an equity investment in Iconix of Mountain View, Calif., and commit additional money and resources to the development partnership. Other financial details of the partnership were not disclosed.
MDS Pharma Services will profile thousands of benchmark drug molecules to create a standardized source of comprehensive pharmacological information on both successful and unsuccessful drug candidates. Iconix will provide genomic expression array profiling and chemical indexing of the molecules.
Privately held Iconix is known for its work in the field of “chemogenomics,” the effort to connect genomic data with information about pharmacology, toxicology and drug molecule structure.
Iconix integrated Incyte’s LifeExpress Lead database into its current chemogenomics system. Incyte has exclusive marketing rights to the new platform.